Anti-inflammatory effect of simvastatin in an experimental model of spinal cord trauma: involvement of PPAR-α

详细信息    查看全文

• 作者：Emanuela Esposito (1)
  Barbara Rinaldi (2)
  Emanuela Mazzon (1) (3)
  Maria Donniacuo (2)
  Daniela Impellizzeri (1)
  Irene Paterniti (1)
  Annalisa Capuano (2)
  Placido Bramanti (1) (3)
  Salvatore Cuzzocrea (1)
  
• 关键词：SCI ; PPAR ; α ; simvastatin ; inflammation
• 刊名：Journal of Neuroinflammation
• 出版年：2012
• 出版时间：December 2012
• 年：2012
• 卷：9
• 期：1
• 全文大小：1139KB
• 参考文献：1. Bartholdi D, Schwab ME: Methylprednisolone inhibits early inflammatory processes but not ischemic cell death after experimental spinal cord lesion in the rat. / Brain Res 1995, 672:177-86. CrossRef
  2. Kaltschmidt B, Baeuerle PA, Kaltschmidt C: Potential involvement of the transcription factor NF-kappa B in neurological disorders. / Mol Aspects Med 1993, 14:171-90. CrossRef
  3. Blight AR: Macrophages and inflammatory damage in spinal cord injury. / J Neurotrauma 1992,9(Suppl 1):S83-1.
  4. Samadikuchaksaraei A: An overview of tissue engineering approaches for management of spinal cord injuries. / J Neuroengineering Rehabil 2007, 4:15. CrossRef
  5. Maron DJ, Fazio S, Linton MF: Current perspectives on statins. / Circulation 2000, 101:207-13. CrossRef
  6. Alvarez de Sotomayor M, Vega S, Mingorance C, Marhuenda E, Herrera MD: Effects of HMG-CoA reductase inhibition by simvastatin on vascular dysfunction induced by lipopolysaccharide in rats. / Pharmacology 2008, 82:89-6. CrossRef
  7. Fraunberger P, Grone E, Grone HJ, Walli AK: Simvastatin reduces endotoxin-induced nuclear factor kappaB activation and mortality in guinea pigs despite lowering circulating low-density lipoprotein cholesterol. / Shock 2009, 32:159-63. CrossRef
  8. Jasinska M, Owczarek J, Orszulak-Michalak D: Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. / Pharmacol Rep 2007, 59:483-99.
  9. Giusti-Paiva A, Martinez MR, Felix JV, da Rocha MJ, Carnio EC, Elias LL, Antunes-Rodrigues J: Simvastatin decreases nitric oxide overproduction and reverts the impaired vascular responsiveness induced by endotoxic shock in rats. / Shock 2004, 21:271-75. CrossRef
  10. Stuve O, Youssef S, Steinman L, Zamvil SS: Statins as potential therapeutic agents in neuroinflammatory disorders. / Curr Opin Neurol 2003, 16:393-01. CrossRef
  11. Maggard MA, Ke B, Wang T, Kaldas F, Seu P, Busuttil RW, Imagawa DK: Effects of pravastatin on chronic rejection of rat cardiac allografts. / Transplantation 1998, 65:149-55. CrossRef
  12. Crisby M: Modulation of the inflammatory process by statins. / Drugs Today (Barc) 2003, 39:137-43. CrossRef
  13. Umesono K, Giguere V, Glass CK, Rosenfeld MG, Evans RM: Retinoic acid and thyroid hormone induce gene expression through a common responsive element. / Nature 1988, 336:262-65. CrossRef
  14. Murphy GJ, Holder JC: PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. / Trends Pharmacol Sci 2000, 21:469-74. CrossRef
  15. Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. / Endocr Rev 1999, 20:649-88. CrossRef
  16. Kota BP, Huang TH, Roufogalis BD: An overview on biological mechanisms of PPARs. / Pharmacol Res 2005, 51:85-4. CrossRef
  17. Wayman N, McDonald MC, Thompson AS, Threadgill MD, Thiemermann C: 5-aminoisoquinolinone, a potent inhibitor of poly (adenosine 5'-diphosphate ribose) polymerase, reduces myocardial infarct size. / Eur J Pharmacol 2001, 430:93-00. CrossRef
  18. Moreno S, Farioli-Vecchioli S, Ceru MP: Immunolocalization of peroxisome proliferator-activated receptors and retinoid × receptors in the adult rat CNS. / Neuroscience 2004, 123:131-45. CrossRef
  19. Sher T, Yi HF, McBride OW, Gonzalez FJ: cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. / Biochemistry 1993, 32:5598-604. CrossRef
  20. Yue TL, Bao W, Jucker BM, Gu JL, Romanic AM, Brown PJ, Cui J, Thudium DT, Boyce R, Burns-Kurtis CL, Mirabile RC, Aravindhan K, Ohlstein EH: Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury. / Circulation 2003, 108:2393-399. CrossRef
  21. Moraes LA, Piqueras L, Bishop-Bailey D: Peroxisome proliferator-activated receptors and inflammation. / Pharmacol Ther 2006, 110:371-85. CrossRef
  22. Yang Q, Xie Y, Alexson SE, Nelson BD, DePierre JW: Involvement of the peroxisome proliferator-activated receptor alpha in the immunomodulation caused by peroxisome proliferators in mice. / Biochem Pharmacol 2002, 63:1893-900. CrossRef
  23. Cuzzocrea S, Di Paola R, Mazzon E, Genovese T, Muia C, Centorrino T, Caputi AP: Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors alpha (PPAR-alpha) in the development of inflammatory bowel disease in mice. / Lab Invest 2004, 84:1643-654. CrossRef
  24. Genovese T, Esposito E, Mazzon E, Di Paola R, Muia C, Meli R, Bramanti P, Cuzzocrea S: Effect of cyclopentanone prostaglandin 15-deoxy-delta12,14PGJ2 on early functional recovery from experimental spinal cord injury. / Shock 2008, 30:142-52.
  25. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B: Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. / J Biol Chem 1999, 274:32048-2054. CrossRef
  26. Delerive P, Gervois P, Fruchart JC, Staels B: Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. / J Biol Chem 2000, 275:36703-6707. CrossRef
  27. Okamoto H, Iwamoto T, Kotake S, Momohara S, Yamanaka H, Kamatani N: Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis. / Clin Exp Rheumatol 2005, 23:323-30.
  28. Paumelle R, Blanquart C, Briand O, Barbier O, Duhem C, Woerly G, Percevault F, Fruchart JC, Dombrowicz D, Glineur C, Staels B: Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway. / Circ Res 2006, 98:361-69. CrossRef
  29. Rinaldi B, Donniacuo M, Esposito E, Capuano A, Sodano L, Mazzon E, Di Palma D, Paterniti I, Cuzzocrea S, Rossi F: PPARalpha mediates the anti-inflammatory effect of simvastatin in an experimental model of zymosan-induced multiple organ failure. / Br J Pharmacol 163:609-23.
  30. Zhang S, Rahman M, Zhang S, Qi Z, Thorlacius H: Simvastatin antagonizes CD40L secretion, CXC chemokine formation, and pulmonary infiltration of neutrophils in abdominal sepsis. / J Leukoc Biol 89:735-42.
  31. Mullane KM, Kraemer R, Smith B: Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. / J Pharmacol Methods 1985, 14:157-67. CrossRef
  32. Basso DM, Fisher LC, Anderson AJ, Jakeman LB, McTigue DM, Popovich PG: Basso Mouse Scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains. / J Neurotrauma 2006, 23:635-59. CrossRef
  33. Genovese T, Mazzon E, Mariotto S, Menegazzi M, Cardali S, Conti A, Suzuki H, Bramanti P, Cuzzocrea S: Modulation of nitric oxide homeostasis in a mouse model of spinal cord injury. / J Neurosurg Spine 2006, 4:145-53. CrossRef
  34. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. / Anal Biochem 1976, 72:248-54. CrossRef
  35. Genovese T, Mazzon E, Di Paola R, Cannavo G, Muia C, Bramanti P, Cuzzocrea S: Role of endogenous ligands for the peroxisome proliferators activated receptors alpha in the secondary damage in experimental spinal cord trauma. / Exp Neurol 2005, 194:267-78. CrossRef
  36. Rinaldi B, Donniacuo M, Esposito E, Capuano A, Sodano L, Mazzon E, Di Palma D, Paterniti I, Cuzzocrea S, Rossi F: PPARalpha mediates the anti-inflammatory effect of simvastatin in an experimental model of zymosan-induced multiple organ failure. / Br J Pharmacol 2011, in press.
  37. Kimura T, Mogi C, Tomura H, Kuwabara A, Im DS, Sato K, Kurose H, Murakami M, Okajima F: Induction of scavenger receptor class B type I is critical for simvastatin enhancement of high-density lipoprotein-induced anti-inflammatory actions in endothelial cells. / J Immunol 2008, 181:7332-340.
  38. Baldwin AS Jr: The NF-kappa B and I kappa B proteins: new discoveries and insights. / Annu Rev Immunol 1996, 14:649-83. CrossRef
  39. Beg AA, Finco TS, Nantermet PV, Baldwin AS Jr: Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation. / Mol Cell Biol 1993, 13:3301-310.
  40. Di Marco B, Massetti M, Bruscoli S, Macchiarulo A, Di Virgilio R, Velardi E, Donato V, Migliorati G, Riccardi C: Glucocorticoid-induced leucine zipper (GILZ)/NF-kappaB interaction: role of GILZ homo-dimerization and C-terminal domain. / Nucleic Acids Res 2007, 35:517-28. CrossRef
  41. Viatour P, Merville MP, Bours V, Chariot A: Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. / Trends Biochem Sci 2005, 30:43-2. CrossRef
  42. Kwon BK, Tetzlaff W, Grauer JN, Beiner J, Vaccaro AR: Pathophysiology and pharmacologic treatment of acute spinal cord injury. / Spine J 2004, 4:451-64. CrossRef
  43. Carlson SL, Parrish ME, Springer JE, Doty K, Dossett L: Acute inflammatory response in spinal cord following impact injury. / Exp Neurol 1998, 151:77-8. CrossRef
  44. Fleming JC, Norenberg MD, Ramsay DA, Dekaban GA, Marcillo AE, Saenz AD, Pasquale-Styles M, Dietrich WD, Weaver LC: The cellular inflammatory response in human spinal cords after injury. / Brain 2006, 129:3249-269. CrossRef
  45. Marx N, Duez H, Fruchart JC, Staels B: Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. / Circ Res 2004, 94:1168-178. CrossRef
  46. Delerive P, Fruchart JC, Staels B: Peroxisome proliferator-activated receptors in inflammation control. / J Endocrinol 2001, 169:453-59. CrossRef
  47. Lovett-Racke AE, Hussain RZ, Northrop S, Choy J, Rocchini A, Matthes L, Chavis JA, Diab A, Drew PD, Racke MK: Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. / J Immunol 2004, 172:5790-798.
  48. Bao F, DeWitt DS, Prough DS, Liu D: Peroxynitrite generated in the rat spinal cord induces oxidation and nitration of proteins: reduction by Mn (III) tetrakis (4-benzoic acid) porphyrin. / J Neurosci Res 2003, 71:220-27. CrossRef
  49. Bao F, Liu D: Peroxynitrite generated in the rat spinal cord induces apoptotic cell death and activates caspase-3. / Neuroscience 2003, 116:59-0. CrossRef
  50. Liu D, Bao F, Prough DS, Dewitt DS: Peroxynitrite generated at the level produced by spinal cord injury induces peroxidation of membrane phospholipids in normal rat cord: reduction by a metalloporphyrin. / J Neurotrauma 2005, 22:1123-133. CrossRef
  51. Scott GS, Szabo C, Hooper DC: Poly(ADP-ribose) polymerase activity contributes to peroxynitrite-induced spinal cord neuronal cell death in vitro. / J Neurotrauma 2004, 21:1255-263.
  52. Xiong Y, Rabchevsky AG, Hall ED: Role of peroxynitrite in secondary oxidative damage after spinal cord injury. / J Neurochem 2007, 100:639-49. CrossRef
  53. Xu J, Kim GM, Chen S, Yan P, Ahmed SH, Ku G, Beckman JS, Xu XM, Hsu CY: iNOS and nitrotyrosine expression after spinal cord injury. / J Neurotrauma 2001, 18:523-32. CrossRef
  54. Bolanos JP, Heales SJ, Land JM, Clark JB: Effect of peroxynitrite on the mitochondrial respiratory chain: differential susceptibility of neurones and astrocytes in primary culture. / J Neurochem 1995, 64:1965-972. CrossRef
  55. Alvarez B, Radi R: Peroxynitrite reactivity with amino acids and proteins. / Amino Acids 2003, 25:295-11. CrossRef
  56. Sharma SS, Dhar A, Kaundal RK: FeTPPS protects against global cerebral ischemic-reperfusion injury in gerbils. / Pharmacol Res 2007, 55:335-42. CrossRef
  57. Dhar A, Kaundal RK, Sharma SS: Neuroprotective effects of FeTMPyP: a peroxynitrite decomposition catalyst in global cerebral ischemia model in gerbils. / Pharmacol Res 2006, 54:311-16. CrossRef
  58. Szabo C: Multiple pathways of peroxynitrite cytotoxicity. / Toxicol Lett 2003, 140-41:105-12. CrossRef
  59. Haddad JJ: Antioxidant and prooxidant mechanisms in the regulation of redox(y)-sensitive transcription factors. / Cell Signal 2002, 14:879-97. CrossRef
  60. Crisafulli C, Cuzzocrea S: The role endogenous and exogenous ligands for the peroxisome proliferator-activated receptor alpha (PPAR-alpha) in the regulation of inflammation in macrophages. / Shock 2008,32(1):62-3. CrossRef
  61. Crisafulli C, Bruscoli S, Esposito E, Mazzon E, Di Paola R, Genovese T, Bramanti P, Migliorati G, Cuzzocrea S: PPAR-alpha contributes to the anti-inflammatory activity of 17beta-estradiol. / J Pharmacol Exp Ther 2009, 331:796-07. CrossRef
  62. Takemoto M, Liao JK: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. / Arterioscler Thromb Vasc Biol 2001, 21:1712-719. CrossRef
  63. Benani A, Kremarik-Bouillaud P, Bianchi A, Netter P, Minn A, Dauca M: Evidence for the presence of both peroxisome proliferator-activated receptors alpha and beta in the rat spinal cord. / J Chem Neuroanat 2003, 25:29-8. CrossRef
  64. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W: The PPARalpha-leukotriene B4 pathway to inflammation control. / Nature 1996, 384:39-3. CrossRef
  65. Gonzalez FJ: Recent update on the PPAR alpha-null mouse. / Biochimie 1997, 79:139-44. CrossRef
  66. Sharma K, Wang RX, Zhang LY, Yin DL, Luo XY, Solomon JC, Jiang RF, Markos K, Davidson W, Scott DW, Shi YF: Death the Fas way: regulation and pathophysiology of CD95 and its ligand. / Pharmacol Ther 2000, 88:333-47. CrossRef
  67. Dosreis GA, Borges VM, Zin WA: The central role of Fas-ligand cell signaling in inflammatory lung diseases. / J Cell Mol Med 2004, 8:285-93. CrossRef
  68. Genovese T, Mazzon E, Crisafulli C, Di Paola R, Muia C, Esposito E, Bramanti P, Cuzzocrea S: TNF-alpha blockage in a mouse model of SCI: evidence for improved outcome. / Shock 2008, 29:32-1.
  69. Bauer MK, Vogt M, Los M, Siegel J, Wesselborg S, Schulze-Osthoff K: Role of reactive oxygen intermediates in activation-induced CD95 (APO-1/Fas) ligand expression. / J Biol Chem 1998, 273:8048-055. CrossRef
  70. Siniscalco D, Fuccio C, Giordano C, Ferraraccio F, Palazzo E, Luongo L, Rossi F, Roth KA, Maione S, de Novellis V: Role of reactive oxygen species and spinal cord apoptotic genes in the development of neuropathic pain. / Pharmacol Res 2007, 55:158-66. CrossRef
  71. Xu W, Chi L, Xu R, Ke Y, Luo C, Cai J, Qiu M, Gozal D, Liu R: Increased production of reactive oxygen species contributes to motor neuron death in a compression mouse model of spinal cord injury. / Spinal Cord 2005, 43:204-13. CrossRef
  72. Beattie MS, Hermann GE, Rogers RC, Bresnahan JC: Cell death in models of spinal cord injury. / Prog Brain Res 2002, 137:37-7. CrossRef
  73. Chittenden T, Harrington EA, O'Connor R, Flemington C, Lutz RJ, Evan GI, Guild BC: Induction of apoptosis by the Bcl-2 homologue Bak. / Nature 1995, 374:733-36. CrossRef
  74. Roberts RA, James NH, Woodyatt NJ, Macdonald N, Tugwood JD: Evidence for the suppression of apoptosis by the peroxisome proliferator activated receptor alpha (PPAR alpha). / Carcinogenesis 1998, 19:43-8. CrossRef
  75. Liu PY, Liu YW, Lin LJ, Chen JH, Liao JK: Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. / Circulation 2009, 119:131-38. CrossRef
  76. Ali FY, Armstrong PC, Dhanji AR, Tucker AT, Paul-Clark MJ, Mitchell JA, Warner TD: Antiplatelet actions of statins and fibrates are mediated by PPARs. / Arterioscler Thromb Vasc Biol 2009, 29:706-11. CrossRef
  77. Gao F, Linhartova L, Johnston AM, Thickett DR: Statins and sepsis. / Br J Anaesth 2008, 100:288-98. CrossRef
  
• 作者单位：Emanuela Esposito (1)
  Barbara Rinaldi (2)
  Emanuela Mazzon (1) (3)
  Maria Donniacuo (2)
  Daniela Impellizzeri (1)
  Irene Paterniti (1)
  Annalisa Capuano (2)
  Placido Bramanti (1) (3)
  Salvatore Cuzzocrea (1)
  
  1. Department of Clinical and Experimental Medicine and Pharmacology, School of Medicine, University of Messina, 98125, Messina, Italy
  2. Department of Experimental Medicine, Second University of Naples, via Costantinopoli 16, 80138, Naples, Italy
  3. IRCCS Centro Neurolesi “Bonino-Pulejo- via Provinciale Palermo, C. da Casazza, 98124, Messina, Italy
  
• ISSN：1742-2094

文摘

Background Statins such as simvastatin are inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase used in the prevention of cardiovascular disease. In addition to their cholesterol-lowering activities, statins exert pleiotropic anti-inflammatory effects, which might contribute to their beneficial effects on lipid-unrelated inflammatory diseases. Recently it has been demonstrated that the peroxisome proliferator-activated receptor (PPAR)-α mediates anti-inflammatory effects of simvastatin in vivo models of acute inflammation. Moreover, previous results suggest that PPAR-α plays a role in control of secondary inflammatory process associated with spinal cord injury (SCI). Methods With the aim to characterize the role of PPAR-α in simvastatin activity, we tested the efficacy of simvastatin (10 mg/kg dissolved in saline i.p. 1 h and 6 h after the trauma) in an experimental model of SCI induced in mice by extradural compression of the spinal cord (T6-T7 level) using an aneurysm clip with a closing force of 24 g via a four-level T5-T8 laminectomy, and comparing mice lacking PPAR-α (PPAR-α KO) with wild type (WT) mice. In order to elucidate whether the effects of simvastatin are due to activation of the PPAR-α, we also investigated the effect of a PPAR-α antagonist, GW6471 (1 mg/kg administered i.p. 30 min prior treatment with simvastatin) on the protective effects of on simvastatin. Results Results indicate that simvastatin activity is weakened in PPAR-α KO mice, as compared to WT controls. In particular, simvastatin was less effective in PPAR-α KO, compared to WT mice, as evaluated by inhibition of the degree of spinal cord inflammation, neutrophil infiltration, nitrotyrosine formation, pro-inflammmatory cytokine expression, nuclear factor (NF)-κB activation, inducible nitric-oxide synthase (iNOS) expression, and apoptosis. In addition we demonstrated that GW6471 significantly antagonized the effect of the statin and thus abolished the protective effect. Conclusions This study indicates that PPAR-α can contribute to the anti-inflammatory activity of simvastatin in SCI.